StockNews.AI
WGRX
StockNews.AI
99 days

Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate

1. WGRX reported Q1 2025 revenue of $10.86 million, up from zero last year. 2. Revenue reflects a 36% year-over-year increase on a pro forma basis. 3. The company registered 354 new pharmacies, indicating strong growth potential. 4. Expansion of manufacturer relationships and technology infrastructure is underway. 5. WGRX expects continued momentum in Q2 from operational enhancements.

Earnings
-14.76%Current Return
VS
+4.24%S&P 500
$2.7105/12 07:42 AM EDTEvent Start
$2.3105/13 02:23 PM EDTLatest Updated
8m saved
Insight
Article

FAQ

Why Bullish?

WGRX's first-quarter revenue outperformance signals strong business growth and demand. Historically, positive earnings reports correlate with stock price increases.

How important is it?

The article details significant revenue and operational developments that positively impact investor outlook. The strong Q1 performance and expansion plans suggest potential stock appreciation.

Why Short Term?

Upcoming quarterly results and pharmacy registrations will likely influence immediate investor sentiment. This aligns with past patterns where new contracts led to short-term price boosts.

Related Companies

RXRXAMRXSGAHGEN
Wellgistics Health, Inc. (NASDAQ:WGRX, "Wellgistics Health"), a healthcare infrastructure and pharmaceutical distribution company leveraging proprietary technology, today announced financial results for its first fiscal quarter ended March 31, 2025.Revenue for the Q1 2025 quarter increased to $10.86 million from zero during the comparable period last year on a GAAP basis. Had the Company acquired Wood Sage and Wellgistics LLC as of January 1, 2024, the $10.86 revenue figure of Q1 2025 would be compared to $7.97 million on a pro forma basis for the same period in 2024, representing approximately a 36% year-over-year increase on a non-GAAP basis."Our Q1 growth reflects the momentum we are building across every part of the business," said Brian Norton, CEO of Wellgistics Health. "We're expanding our manufacturer relationships, broadening our product portfolio, and registered 354 new pharmacies this quarter-nearly two-thirds of which have already placed at least one order. We're also laying the groundwork for the next phase of scale with new hub service capabilities and technology infrastructure, including the upcoming expansion of our Peek platform.""Since the IPO in March, Brian has moved with speed and precision to reshape Wellgistics Health into a modern, execution-driven healthcare platform," said Suren Ajjarapu, Chairman of the Board. "He has rebuilt the executive team into one of the most capable leadership groups in the industry and supercharged every aspect of the business-from commercial operations to pharmacy expansion to manufacturer access. This quarter's results are an early indication of what's possible. While we have structured financial tools like the ELOC to support strategic acceleration, we are committed to deploying capital only when it directly fuels outsized growth and market share expansion."Wellgistics Health expects continued momentum in Q2, supported by expanded clinical fulfillment capacity, new manufacturer integrations, and scaled deployment of its pharmacy hub platform.About Wellgistics HealthWellgistics Health, Inc. is a publicly traded healthcare infrastructure company redefining how medications move, are priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a nationwide network of over 6,000 independent pharmacies.Wellgistics Health provides real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment solutions, while equipping pharmacies with integrated financial, clinical, and digital tools. Its end-to-end platform supports a broad range of therapeutic areas from specialty-lite to chronic maintenance medications by eliminating friction, accelerating reimbursements, and enabling direct, transparent connections between manufacturers, providers, pharmacies, and patients.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans, including without limitation its plan in connection with certain financings and cryptocurrencies and outlook and actions with respect to incurring future expenses. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.Note on Non-GAAP Financial MeasuresCertain of the information set forth herein, including revenue on a pro forma basis, may be considered financial measures that are not recognized under United States generally accepted accounting principles, or non-GAAP financial measures. These measures may not be comparable to similar measures presented by other companies. Wellgistics Health defines revenue on a pro forma basis to include revenues as adjusted based on the assumption that Wellgistics Health acquired its two direct subsidiaries, Wood Sage, LLC and Wellgistics, LLC, on January 1, 2024.Wellgistics Health believes this financial information is useful to investors as a measure of profitability, because it helps us compare our performance on a consistent basis by removing from our operating results the impact of our capital structure, the effect of operating in different tax jurisdictions, the impact of our asset base, which can differ depending on the book value of assets and the accounting methods used to compute depreciation and amortization, and the cost of acquiring businesses and restructuring our operations. In addition, the company's management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measures in evaluating the company's operating performance and cash flow. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures as reported by the company may not be comparable to similarly titled amounts reported by other companies.For more information, please contact:Media Contact: [email protected]Investor Relations: [email protected]SOURCE: Wellgistics Health, Inc.

Related News